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A bs tr ac t
Background
Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but 
lipid-lowering studies have had conflicting results.
Methods
We conducted a randomized, double-blind trial involving 1873 patients with mild-to-
moderate, asymptomatic aortic stenosis. The patients received either 40 mg of sim-
vastatin plus 10 mg of ezetimibe or placebo daily. The primary outcome was a com-
posite of major cardiovascular events, including death from cardiovascular causes, 
aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable 
angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary 
intervention, and nonhemorrhagic stroke. Secondary outcomes were events related to 
aortic-valve stenosis and ischemic cardiovascular events.
Results
During a median follow-up of 52.2 months, the primary outcome occurred in 333 
patients (35.3%) in the simvastatin–ezetimibe group and in 355 patients (38.2%) in the 
placebo group (hazard ratio in the simvastatin–ezetimibe group, 0.96; 95% confi-
dence interval [CI], 0.83 to 1.12; P = 0.59). Aortic-valve replacement was performed in 
267 patients (28.3%) in the simvastatin–ezetimibe group and in 278 patients (29.9%) 
in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P = 0.97). Fewer pa-
tients had ischemic cardiovascular events in the simvastatin–ezetimibe group (148 
patients) than in the placebo group (187 patients) (hazard ratio, 0.78; 95% CI, 0.63 
to 0.97; P = 0.02), mainly because of the smaller number of patients who underwent 
coronary-artery bypass grafting. Cancer occurred more frequently in the simvastatin–
ezetimibe group (105 vs. 70, P = 0.01).
Conclusions
Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-
valve events and ischemic events in patients with aortic stenosis. Such therapy reduced 
the incidence of ischemic cardiovascular events but not events related to aortic-valve 
stenosis. (ClinicalTrials.gov number, NCT00092677.)
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A ortic-valve stenosis is common in elderly persons, with a prevalence of 3 to 5% in the population over 75 years of age.1,2 
The condition has been shown to be an inflam-
matory process associated with cardiovascular risk 
factors, with histopathological changes in the valve 
leaflets that are similar to those in other athero-
sclerotic diseases.2-19 Changes in the aortic valve 
are associated with an increased risk of death 
from cardiovascular causes and myocardial infarc-
tion, even in the absence of hemodynamic obstruc-
tion and signs of coronary disease.20-22 The stan-
dard treatment is surgical replacement when the 
valve becomes severely stenotic.23,24
Epidemiologic2 and genetic25,26 studies have 
identified risk factors for the development of 
aortic-valve stenosis, and experimental work has 
elucidated the cellular mechanisms involved in 
disease progression, many of which resemble 
atherosclerosis.27-30 One interpretation of these 
findings is that lipid-lowering treatment might 
prevent progression of aortic-valve stenosis and 
thus reduce the need for aortic-valve replacement.
The effect of statin treatment on aortic-valve 
stenosis has been assessed in several retrospective 
or small case–control studies.27,31-33 Most stud-
ies have suggested a beneficial effect of statins, 
whereas one prospective, randomized study did 
not find any effect of lipid-lowering therapy on 
the progression of aortic-valve stenosis.34
The Simvastatin and Ezetimibe in Aortic Steno-
sis (SEAS) trial was designed to study the effects 
of long-term, intensive cholesterol lowering with 
daily use of simvastatin and ezetimibe on clinical 
and echocardiographic outcomes in patients with 
asymptomatic, mild-to-moderate aortic-valve sten-
o sis and no other indication for lipid-lowering 
treatment.
Me thods
Patient Population
The study design and baseline characteristics of 
the patients have been reported previously.35 Men 
and women between the ages of 45 and 85 years 
who had asymptomatic, mild-to-moderate aortic-
valve stenosis, as assessed on echocardiography, 
with a peak aortic-jet velocity of 2.5 to 4 m per sec-
ond, were eligible for the study. Patients were ex-
cluded if they had received a diagnosis or had 
symptoms of coronary artery disease, peripheral 
arterial disease, cerebrovascular disease, or dia-
betes mellitus or if they had any other condition 
requiring lipid-lowering therapy. The study was ap-
proved by all relevant institutional ethics commit-
tees or by ethics committees in each country, and 
all patients provided written informed consent.
Study Protocol
The study was initiated by the investigators and was 
designed by the steering committee on the basis of 
a protocol developed for the Simvastatin in Aortic 
Stenosis (SAS) study,35 which evaluated the effect 
of lipid-lowering therapy with simvastatin (at a dose 
of 40 to 80 mg) as compared with placebo on clin-
ical and echocardiographic outcomes in patients 
with aortic stenosis. The SAS study was sponsored 
by Merck but was otherwise managed by the SAS 
study steering committee.
From March 2001 through December 2002, 
a total of 196 patients underwent randomization. 
To improve the lipid-lowering effect while decreas-
ing the risk of myopathy, the steering committee 
decided to add ezetimibe (at a dose of 10 mg daily) 
to 40 mg of simvastatin in the larger SEAS trial, 
as suggested by the sponsor. The responsibility for 
the logistics of the SEAS trial was transferred to 
the sponsor, but the scientific responsibility re-
mained with the independent steering committee, 
which included two nonvoting members of the 
sponsor.35 The patients who were assigned to re-
ceive simvastatin in the SAS study remained in the 
active-treatment group in the SEAS trial, in which 
ezetimibe was added to simvastatin, and the pa-
tients in the SAS placebo group remained in the 
SEAS placebo group. During this process, neither 
the patients nor the investigators were aware of 
study-group assignments. After a 4-week run-in 
period in which all patients were given single-
blind placebo tablets and were instructed to fol-
low a lipid-lowering diet according to the recom-
mendations of the National Cholesterol Education 
Program,36 eligible patients underwent random-
ization in a 1:1 fashion in blocks of two to receive 
either simvastatin–ezetimibe or placebo (Fig. 1).
Open-label lipid-lowering therapy, which in-
cluded up to 40 mg of simvastatin or an equipo-
tent dose of another lipid-lowering drug, could be 
administered in addition to the study drug at the 
discretion of each treating physician, although 
patients and investigators remained unaware of 
study-group assignments. The numbers of pa-
tients receiving open-label therapy are shown 
in Figure 1.
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The study was completed according to the pro-
tocol when all patients had been followed for a 
minimum of 4 years after randomization, at which 
point the primary outcome had occurred in at least 
464 patients.35
The SEAS steering committee designed the 
study and vouches for the accuracy and complete-
ness of the data and the analysis. The sponsor 
gathered the data; the Echocardiography Core 
Laboratory read the locally recorded echocardio-
grams. The statistical analysis was performed by 
Merck, according to a predefined protocol. In ad-
dition, parallel statistical analysis with the use of 
SPSS software (version 15.0) was performed on raw 
data by an independent statistician, a process 
that generated identical results. The first draft of 
the manuscript was written by the lead academic 
author.
Efficacy Outcomes
The primary outcome of the study was major car-
diovascular events, a composite consisting of death 
from cardiovascular causes, aortic-valve replace-
ment, congestive heart failure as a result of pro-
gression of aortic-valve stenosis, nonfatal myocar-
dial infarction, hospitalization for unstable angina, 
coronary-artery bypass grafting (CABG), percuta-
neous coronary intervention (PCI), or nonhemor-
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Figure 1. Enrollment and Outcomes.
SAS denotes the Simvastatin in Aortic Stenosis Study.
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rhagic stroke. The primary composite outcome 
included aortic-valve–related clinical events and 
ischemic events to account for possible cardiovas-
cular symptoms and events occurring in patients 
with aortic-valve stenosis.21
Key secondary outcomes were aortic-valve events 
(which were defined as aortic-valve replacement 
surgery, congestive heart failure due to aortic 
stenosis, or death from cardiovascular causes) and 
ischemic events (which were defined as death from 
cardiovascular causes, nonfatal myocardial infarc-
tion, hospitalization for unstable angina, CABG, 
PCI, or nonhemorrhagic stroke). Other secondary 
objectives were progression of aortic stenosis, as 
seen on echocardiography, and the safety of the 
study drugs.
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Placebo 
(N = 929)
Simvastatin–
Ezetimibe 
(N = 944) P Value†
Age — yr 67.4±9.7 67.7±9.4 0.46
Female sex — no. (%) 360 (38.8) 363 (38.5) 0.92
White race — no. (%)‡ 928 (99.9) 940 (99.6) NA
Blood pressure — mm Hg 
Systolic 144.0±20.0 145.6±20.4 0.08
Diastolic 82.0±10.0 82.0±10.6 0.98
Hypertension — no. (%) 476 (51.2) 489 (51.8) 0.82
Smoking status — no. (%) 0.59
Current 171 (18.4) 189 (20.0)
Former 344 (37.0) 333 (35.3)
Never 414 (44.6) 422 (44.7)
Body-mass index 26.8±4.3 26.9±4.3 0.58
Atrial fibrillation — no. (%)§ 90 (9.7) 87 (9.2) 0.75
Atrioventricular block — no. (%) 23 (2.5) 21 (2.2) 0.76
Benign prostatic hyperplasia — no. of men (%) 63 (11.1) 74 (12.7) 0.47
Neoplasm (benign, malignant, or unspecified) — no. (%) 103 (11.1) 79 (8.4) 0.05
Drug therapy — no. (%) 
Angiotensin-converting–enzyme inhibitor 149 (16.0) 139 (14.7) 0.44
Angiotensin-receptor blocker 98 (10.5) 95 (10.1) 0.76
Calcium antagonist 160 (17.2) 157 (16.6) 0.76
Beta-blocker 268 (28.8) 242 (25.6) 0.12
Aspirin or other platelet inhibitor 260 (28.0) 236 (25.0) 0.16
Anticoagulant agent 49 (5.3) 58 (6.1) 0.43
Diuretic (including spironolactone) 229 (24.7) 209 (22.1) 0.21
Digitalis glycoside 22 (2.4) 28 (3.0) 0.47
Laboratory values
Glucose — mg/dl 96.2±15.5 96.3±14.7 0.95
Creatinine — mg/dl 1.06±0.17 1.06±0.18 0.82
Estimated glomerular filtration rate — ml/min per 1.73 m2¶ 68.2±12.0 68.5±12.6 0.54
High-sensitivity C-reactive protein — mg/liter 0.76
Median 2.20 2.10
Interquartile range 0.90–4.90 0.90–4.10
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All outcomes were classified by an independent 
end-point classification committee whose mem-
bers were unaware of study-group assignments. 
The data and safety monitoring board performed 
four preplanned interim analyses of efficacy and 
safety,35 as well as two extra analyses of safety.
Echocardiography was performed at baseline 
and then annually and before valve surgery, ac-
cording to a standardized echocardiographic pro-
tocol.37 All images were recorded on Video Home 
System videotape or digitally in Digital Imaging 
and Communications in Medicine format on com-
pact disk or magneto-optical disk and were for-
warded to the SEAS Echocardiography Core Labo-
ratory at Haukeland University Hospital in Bergen, 
Norway. All readings were performed according to 
the American Society of Echocardiography guide-
lines38 with the use of an off-line digital comput-
erized review system on workstations with Image 
Arena software (TomTec Imaging Systems). The 
readers were unaware of the sequence and site in 
order to minimize bias.
Statistical Analysis
The study outcomes were analyzed according to 
the intention-to-treat principle. The study had a 
power of 90% to detect a reduction of 22% in the 
relative risk of the primary outcome. For all time-
Table 1. (Continued.)
Characteristic
Placebo 
(N = 929)
Simvastatin–
Ezetimibe 
(N = 944) P Value†
Lipids
Cholesterol
Total — mg/dl 221±38 223±40 0.41
LDL — mg/dl  139±35 140±36 0.42
HDL — mg/dl 58±17 58±17 0.87
Ratio of total cholesterol to HDL cholesterol 4.13±1.39 4.12±1.22 0.81
Non-HDL cholesterol — mg/dl  164±38 165±39 0.46
Triglycerides — mg/dl 126±60 126±63 0.93
Apolipoprotein B — mg/dl 130±28 132±28 0.37
Echocardiographic measures
Peak aortic-jet velocity — m/sec 3.10±0.54 3.09±0.55 0.67
Transaortic pressure gradient — mm Hg
Peak 39.6±13.8 39.3±13.9 0.70
Mean 23.0±8.7 22.7±8.8 0.42
Aortic valve
Area — cm2 1.27±0.46 1.29±0.48 0.29
Area index — cm2/m2 0.67±0.23 0.68±0.24 0.35
Bicuspid valve — no. (%) 47 (6.3) 38 (5.0) 0.32
Left ventricular mass — g 194.5±69.4 194.1±66.8 0.92
Left ventricular ejection fraction — % 66±7 67±6 0.56
* Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height 
in meters. To convert values for glucose to millimoles per liter, multiply by 0.05551. To convert values for creatinine to 
micromoles per liter, multiply by 88.4. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To 
convert values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, LDL 
low-density lipoprotein, and NA not applicable. 
† P values for baseline comparisons were not included in the statistical analysis plan.
‡ Race was determined by the investigators.  
§ Atrial fibrillation included past events and those that were intermittent, constant, or present at the baseline visit, as well 
as atrial flutter.
¶ The glomerular filtration rate was calculated with the formula used in the Modification of Diet in Renal Disease Study, 
which accounts for age, sex, race, and calibration of the serum creatinine level.  
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to-event outcomes, survival analytic methods were 
used, with analyses based on a Cox proportional-
hazards model.
Analyses were performed with the use of SAS 
software, version 8.2. For aortic-stenosis progres-
sion, the analysis included data from all patients 
with at least one baseline and one follow-up mea-
surement. For analyses of adverse events, confi-
dence intervals for differences in proportions of 
patients were computed with the method of Mi-
ettinen and Nurminen and with Fisher’s exact test, 
when appropriate. Tests were generally performed 
at a two-sided significance level of 0.05, except that 
for the primary outcome, which was performed at 
a significance level of 0.0490 to account for in-
terim analyses.
Data on adverse events were collected from all 
patients who underwent follow-up and analysis, 
with the exception of nonfatal events that did not 
require hospitalization and that occurred at least 
15 days after the discontinuation of study drug or 
placebo, according to the protocol.
R esult s
Patients
A total of 1873 patients underwent randomiza-
tion at 173 study sites in seven European coun-
tries.35 Of these patients, 944 were assigned to re-
ceive 40 mg of simvastatin and 10 mg of ezetimibe 
daily, and 929 were assigned to receive placebo. 
Baseline demographic, laboratory, and echocardio-
graphic data for the two study groups are shown 
in Table 1. The median follow-up period was 52.2 
months.
Lipids
The mean serum level of low-density lipoprotein 
(LDL) cholesterol remained unchanged in the pla-
cebo group and decreased by 61.3%, to a mean 
(±SD) level of 53±23 mg per deciliter (1.36±0.60 
mmol per liter) at 8 weeks, in the simvastatin–
ezetimibe group. During the entire follow-up pe-
riod, the mean percent reduction in LDL choles-
terol was 53.8% in the simvastatin–ezetimibe group 
and 3.8% in the placebo group (Fig. 2A).
Outcome Measures
The primary composite outcome occurred in 333 
patients (35.3%) in the simvastatin–ezetimibe group 
and in 355 patients (38.2%) in the placebo group 
(hazard ratio in the simvastatin–ezetimibe group, 
0.96; 95% confidence interval [CI], 0.83 to 1.12; 
P = 0.59) (Table 2 and Fig. 3A).
There was no significant difference between 
the two study groups in the secondary outcome of 
aortic-valve–related events, including aortic-valve 
replacement, death from cardiovascular causes, 
and hospitalization for heart failure as a conse-
quence of progression of aortic stenosis (hazard 
ratio, 0.97; 95% CI, 0.83 to 1.14; P = 0.73) (Fig. 3B). 
The principal component of this secondary com-
posite outcome was aortic-valve replacement, which 
occurred in 267 patients (28.3%) in the simva-
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Figure 2. Serum Low-Density Lipoprotein (LDL)  
Cholesterol Levels (Panel A) and the Change from 
Baseline in Peak Aortic-Jet Velocity (Panel B).
The I bars represent standard errors. In Panel A, the 
first data points correspond to results at the 8-week 
visit.
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Table 2. Prespecified Primary and Secondary Composite Outcomes and Death.*
Outcome
Placebo
(N = 929)
Simvastatin plus 
Ezetimibe
(N = 944)
Hazard Ratio
(95% CI)† P Value
number (percent)
Primary outcome 
Patients with any event‡ 355 (38.2) 333 (35.3) 0.96 (0.83–1.12) 0.59
Death from cardiovascular causes 56 (6.0) 47 (5.0) 0.83 (0.56–1.22) 0.34
Aortic-valve replacement surgery 278 (29.9) 267 (28.3) 1.00 (0.84–1.18) 0.97
Congestive heart failure as a result of progression of aortic 
stenosis
23 (2.5) 25 (2.6) 1.09 (0.62–1.92) 0.77
Nonfatal myocardial infarction 26 (2.8) 17 (1.8) 0.64 (0.35–1.17) 0.15
Coronary-artery bypass grafting 100 (10.8) 69 (7.3) 0.68 (0.50–0.93) 0.02
Percutaneous coronary intervention 17 (1.8) 8 (0.8) 0.46 (0.20–1.06) NA
Hospitalization for unstable angina 8 (0.9) 5 (0.5) 0.61 (0.20–1.86) NA
Nonhemorrhagic stroke 29 (3.1) 33 (3.5) 1.12 (0.68–1.85) 0.65
Secondary outcomes
Aortic-valve events 326 (35.1) 308 (32.6) 0.97 (0.83–1.14) 0.73
Aortic-valve replacement surgery 278 (29.9) 267 (28.3) 1.00 (0.84–1.18) 0.97
Congestive heart failure as a result of progression of aortic 
stenosis 
23 (2.5) 25 (2.6) 1.09 (0.62–1.92) 0.77
Death from cardiovascular causes§ 56 (6.0) 47 (5.0) 0.83 (0.56–1.22) 0.34
Ischemic events 187 (20.1) 148 (15.7) 0.78 (0.63– 0.97) 0.02
Nonfatal myocardial infarction 26 (2.8) 17 (1.8) 0.64 (0.35–1.17) 0.15
Coronary-artery bypass grafting 100 (10.8) 69 (7.3) 0.68 (0.50– 0.93) 0.02
Percutaneous coronary intervention 17 (1.8) 8 (0.8) 0.46 (0.20–1.06) NA
Hospitalization for unstable angina 8 (0.9) 5 (0.5) 0.61 (0.20–1.86) NA
Nonhemorrhagic stroke 29 (3.1) 33 (3.5) 1.12 (0.68–1.85) 0.65
Death from cardiovascular causes§ 56 (6.0) 47 (5.0) 0.83 (0.56–1.22) 0.34
Death
From any cause 100 (10.8) 105 (11.1) 1.04 (0.79–1.36) 0.80
From cardiovascular causes 56 (6.0) 47 (5.0) 0.83 (0.56–1.22) 0.34
Myocardial infarction 10 (1.1) 5 (0.5) 0.49 (0.17–1.42) 
Stroke 6 (0.6) 5 (0.5) 0.82 (0.25–2.70) 
Sudden death 20 (2.2) 20 (2.1) 0.99 (0.53–1.83) 
Related to cardiac surgery (perioperative) 7 (0.8) 7 (0.7) 0.99 (0.35–2.83) 
Heart failure 5 (0.5) 6 (0.6) 1.21 (0.37–3.95) 
Other 8 (0.9) 4 (0.4) 0.49 (0.15–1.63) 
From noncardiovascular causes 44 (4.7) 56 (5.9) 1.26 (0.85–1.86) 0.26
Cancer¶ 23 (2.5) 39 (4.1) 1.67 (1.00–2.79) 0.05
Infection 14 (1.5) 7 (0.7) 0.50 (0.20–1.23) 
Violence or accident 1 (0.1) 3 (0.3) 2.95 (0.31–28.4) 
Other 6 (0.6) 7 (0.7) 1.15 (0.39–3.42) 
Could not be classified 0 2 (0.2)
* NA denotes not applicable because of the small number of events.
† The hazard ratio is for the simvastatin–ezetimibe group versus the placebo group.
‡ Patients could have more than one event. 
§ All deaths from cardiovascular causes were included in both secondary outcomes.
¶ Numbers include recurrent cancers in three patients in the placebo group and one patient in the simvastatin–ezetimibe group. One patient 
in the simvastatin–ezetimibe group died from cancer that was diagnosed in the SAS study before randomization in the SEAS study.
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statin–ezetimibe group and in 278 patients (29.9%) 
in the placebo group (hazard ratio, 1.00; 95% CI, 
0.84 to 1.18; P = 0.97).
There were fewer patients with the secondary 
composite outcome of ischemic cardiovascular 
events in the simvastatin–ezetimibe group (148 
patients, or 15.7%) than in the placebo group (187 
patients, or 20.1%) (hazard ratio, 0.78; 95% CI, 
0.63 to 0.97; P = 0.02) (Table 2 and Fig. 3C). The 
treatment effect was dominated by a significant 
reduction in the need for CABG, with 69 patients 
(7.3%) in the simvastatin–ezetimibe group, as 
compared with 100 patients (10.8%) in the placebo 
group, undergoing the procedure (hazard ratio, 
0.68; 95% CI, 0.50 to 0.93; P = 0.02). All but one 
of the CABG procedures were performed together 
with aortic-valve replacement.
Effect on Progression
In the placebo group, the mean (±SD) peak aortic-
jet velocity was 3.71±0.76 m per second at the end 
of the study, an increase of 0.62±0.61 m per sec-
ond. This change was similar to that in the sim-
vastatin–ezetimibe group, in which the velocity 
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Figure 3. Kaplan–Meier Curves for Primary and Secondary Outcomes and Death.
The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replace-
ment, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percuta-
neous coronary intervention, and nonhemorrhagic stroke (Panel A). Secondary outcomes were events related to aortic-valve stenosis 
(Panel B) and ischemic cardiovascular events (Panel C). There was no difference between the study groups in overall mortality (Panel D).
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was 3.69±0.78 m per second at the end of the study, 
an increase of 0.61±0.59 m per second (95% CI, 
−0.06 to 0.05; P = 0.83) (Fig. 2B). This was the pre-
defined key echocardiographic measure for the 
evaluation of progression of aortic stenosis. In the 
placebo group, the mean pressure gradient was 
22.5±8.5 mm Hg at baseline and increased to 
34.4±14.9 mm Hg at the end of the study, as com-
pared with a value of 22.2±8.5 mm Hg at baseline 
with an increase to 34.0±15.1 mm Hg in the sim-
vastatin–ezetimibe group. Neither the difference 
between the two groups at either time point nor 
the difference in the change from baseline in 
the aortic-valve area was significant. Annualized 
changes in the mean (±SE) peak aortic-jet veloc-
ity were 0.15±0.01 m per second per year in the 
simvastatin–ezetimibe group and 0.16±0.01 m 
per second per year in the placebo group. The 
mean transaortic pressure gradient increased by 
2.7±0.1 mm Hg per year in the simvastatin–ezeti-
mibe group and by 2.8±0.1 mm Hg per year in the 
placebo group. There was an annualized reduc-
tion in the aortic-valve area of 0.03±0.01 cm2 per 
year in each of the two groups.
Mortality
There was no significant difference between the 
study groups in overall mortality (Table 2 and Fig. 
3D). The composite outcome of death from car-
diovascular causes and the components of this 
composite outcome also did not differ significant-
ly between the two groups.
Deaths from noncardiovascular causes occurred 
in 56 patients (5.9%) in the simvastatin–ezetimibe 
group and in 44 patients (4.7%) in the placebo 
group (hazard ratio in the simvastatin–ezetimibe 
group, 1.26; 95% CI, 0.85 to 1.86; P = 0.26). The 
numbers of fatal cancers were 39 (4.1%) in the 
simvastatin–ezetimibe group and 23 (2.5%) in the 
placebo group (hazard ratio, 1.67; 95% CI, 1.00 
to 2.79; P = 0.05 according to the prespecified 
data-analysis plan; P = 0.06 with Yates’ continuity 
correction) (Table 2). Of these patients, one in 
the simvastatin–ezetimibe group and three in the 
placebo group died from recurrent cancers, plus 
one patient in the simvastatin–ezetimibe group 
died from cancer that was diagnosed in the SAS 
trial, before entry into the SEAS trial.
Adverse Events
There was a significant increase in the number of 
patients with elevated liver enzyme levels in the 
simvastatin–ezetimibe group, as compared with 
the placebo group, during the study period (Ta-
ble 3). There were no differences in clinical, or-
gan-related adverse events, except for significantly 
higher incident cancers in the simvastatin–ezeti-
mibe group (Table 3).
Cancer
In the simvastatin–ezetimibe group, incident can-
cer was diagnosed in 105 patients (11.1%), as com-
pared with 70 patients (7.5%) in the placebo group 
(P = 0.01). Cancers that had been diagnosed before 
randomization recurred in eight of these patients 
(three in the simvastatin–ezetimibe group and 
five in the placebo group), and one patient had a 
cancer that developed during the SAS trial, before 
enrollment in the SEAS trial. The excess cancers 
in the simvastatin–ezetimibe group were not clus-
tered at any particular site (Table 4). In addition, 
the risk of incident cancer was not associated 
with the degree of LDL-cholesterol lowering. Fig-
ure 4 shows Kaplan–Meier curves for cancer-related 
mortality in the two study groups.
Discussion
The combination of simvastatin and ezetimibe re-
sulted in an average reduction in LDL cholesterol 
of at least 50%, as compared with placebo. De-
spite this favorable effect over a minimum period 
of 4 years, there was no overall effect on aortic-
valve stenosis and no significant overall effect on 
the composite primary outcome. The lack of any 
effect on the progression of aortic stenosis as seen 
on echocardiography supports the conclusion that 
the lack of effect on clinical valve-related events 
was real and not due to a lack of statistical power. 
The finding of increased numbers of incident and 
fatal cancers in the simvastatin–ezetimibe group, 
as compared with the placebo group, was unex-
pected and requires further exploration in trials 
of simvastatin and ezetimibe.
The lack of effect on aortic-valve stenosis is 
in agreement with the findings of the smaller 
Scottish Aortic Stenosis and Lipid Lowering 
Trial, Impact on Regression (SALTIRE) study, in 
which atorvastatin was used.34 The results of the 
Rosuvastatin Affecting Aortic Valve Endotheli-
um (RAAVE) study (ClinicalTrials.gov number, 
NCT00114491) indicated a favorable effect on aor-
tic stenosis, but the study had a nonrandomized 
and open-label design, with comparisons of vari-
ous categories of patients with aortic stenosis.39
Our study population did not represent all pa-
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Table 3. Adverse Events (Safety Population).*
Event
Placebo
(N = 929)
Simvastatin plus 
Ezetimibe
(N = 943) P Value†
no./total no. (%)
Clinical 
Any event 852 (91.7) 854 (90.6)
Any serious event‡ 463 (49.8) 468 (49.6)
Incident cancer§ 70 (7.5) 105 (11.1) 0.01
Recurrent cancer 5 (0.5) 3 (0.3)
New cancer 65 (7.0) 102 (10.8)¶ 0.01
New cancer after ezetimibe 65 (7.0) 101 (10.7) 0.01
Event attributed to study treatment‖
Any 110 (11.8) 134 (14.2)
Serious 3 (0.3) 5 (0.5)
Event resulting in permanent discontinuation of study treatment
Any 122 (13.1) 144 (15.3)
Attributed to treatment 29 (3.1) 46 (4.9)
Serious event resulting in permanent discontinuation of study treatment
Any 79 (8.5) 77 (8.2)
Attributed to treatment 1 (0.1) 2 (0.2)
Musculoskeletal condition 181 (19.5) 165 (17.5) 0.28
Hepatitis 6 (0.6) 5 (0.5) 0.77
Gastrointestinal condition 281 (30.2) 308 (32.7) 0.27
Gallbladder-related condition  11 (1.2) 10 (1.1) 0.83
Allergic reaction or rash 102 (11.0) 104 (11.0) 1.00
Laboratory findings
Creatine kinase
>10 times ULN without muscle-related symptoms 2/915 (0.2) 2/925 (0.2) 1.00
>10 times ULN with muscle-related symptoms 0 0 NA
>10 times ULN with muscle-related symptoms and drug  
relationship
0 0 NA
Liver enzymes
Alanine aminotransferase or aspartate aminotransferase  
≥3 times ULN (consecutive)**
5/915 (0.5) 16/925 (1.7) 0.03
* Listed are the numbers of patients who had at least one event (or elevated value) during the study period, with each 
event counted only once within a category. Patients could have more than one event in different categories. The de-
nominators are the numbers of patients who received at least one dose of study drug or placebo. One patient who  
underwent randomization was not included in the safety analyses because he did not receive study drug or placebo.  
NA denotes not applicable, and ULN upper limit of the normal range.
† P values were not calculated for comparisons between small numbers and for those for which there was no a priori 
hypothesis, with the exception of cancer.
‡ Serious adverse events included fatal or life-threatening conditions, those resulting in hospitalization or persistent 
disability, cancer, and any drug overdose.
§ This category includes 11 patients whose fatal cancers were diagnosed after the discontinuation of study drug or pla-
cebo and were therefore not reported as serious adverse events, according to the study protocol.
¶ This number includes one patient who had a newly diagnosed cancer before randomization in the SEAS study.
‖ Events attributed to study treatment were those that were determined by the investigator to be associated with study 
drug or placebo. 
** This category includes patients with values that were three or more times the ULN at two or more consecutive visits, 
the single last visit, or at least one visit, with a subsequent value that was less than three times the ULN when mea-
sured more than 2 days after the last dose of study drug or placebo.
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tients with aortic-valve stenosis, since high-risk 
patients with severe hyperlipidemia requiring ac-
tive lipid-lowering treatment, known atheroscle-
rotic disease, or diabetes mellitus were not in-
cluded in order to allow for placebo treatment. 
This factor may explain the relatively low rate of 
progression of aortic-valve stenosis in our study, 
as compared with that in other studies.34,40 Oth-
erwise, the patients in our study had character-
istics that are typical of patients with aortic steno-
sis. It is possible that treatment in our study was 
initiated too late in the course of the disease to 
affect further progression, but it is also possible 
that high levels of LDL cholesterol are just a mark-
er for progression of stenosis.
Therapy with simvastatin and ezetimibe result-
ed in a significant reduction in the risk of ische-
mic cardiovascular events, mainly through fewer 
CABG procedures. Since nearly all coronary sur-
gery was performed as a combined procedure with 
aortic-valve replacement, the study-drug regimen 
may have had a substantial effect on atheroscle-
rosis, as shown on coronary angiography. How-
ever, the reduction in the risk of other components 
of the secondary ischemic outcome was smaller 
than expected on the basis of the large reduction 
in LDL cholesterol levels.41 There was a weaker 
relationship between baseline LDL cholesterol lev-
els and any ischemic event in the placebo group 
than was seen in studies in high-risk populations, 
suggesting less potential for risk reduction with 
lipid-lowering therapy.
Long-term statin therapy has not been associ-
ated with an increased risk of cancer. Analysis of 
data from 14 statin trials involving approximately 
90,000 patients showed no evidence of an in-
creased incidence of or death from cancer.41 How-
ever, ezetimibe has been studied less extensively 
than statins, and the finding of a significant dif-
ference between the two study groups in the num-
Table 4. Incident Cancer (Safety Population).
Site
Placebo
(N = 929)
Simvastatin plus 
Ezetimibe
(N = 943) P Value*
number (percent)
Any cancer† 70 (7.5) 105 (11.1) 0.01
Any cancer excluding recurrent cancer 65 (7.0) 102 (10.8)‡ 0.01
Lip, mouth, pharynx, or esophagus 1 (0.1) 1 (0.1) 1.0
Stomach 1 (0.1) 5 (0.5) 0.23
Large bowel or intestine 8 (0.9) 9 (1.0) 1.0
Pancreas 1 (0.1) 4 (0.4) 0.38
Liver, gallbladder, or bile ducts 3 (0.3) 2 (0.2) 1.0
Lung 10 (1.1) 7 (0.7) 0.60
Other respiratory organ 0 1 (0.1) 1.0
Skin 8 (0.9) 18 (1.9) 0.08
Breast 5 (0.5) 8 (0.8) 0.60
Prostate 13 (1.4) 21 (2.2) 0.24
Kidney 2 (0.2) 2 (0.2) 1.0
Bladder 7 (0.8) 7 (0.7) 1.0
Genital 4 (0.4) 4 (0.4) 1.0
Hematologic 5 (0.5) 7 (0.7) 0.79
Other known sites 1 (0.1) 3 (0.3) 0.63
Unspecified 6 (0.6) 9 (1.0) 0.63
* All P values were calculated with Yates’ continuity correction because of small numbers.
† The numbers of patients include those with any cancers including recurrent cancer. One patient who underwent ran-
domization was not included in the safety analyses because he did not receive study drug or placebo. Some patients 
had more than one site of cancer. The numbers per anatomical site exclude recurrent cancers.
‡ This number includes one patient whose cancer was diagnosed after entry in the SAS study but before randomization 
in the SEAS study.
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bers of patients with new and fatal cancers is a 
concern. In this issue of the Journal, Peto et al.42 
describe the results of an independent analysis of 
preliminary data on cancer from two large, ongo-
ing studies, the Study of Heart and Renal Protec-
tion (SHARP) (NCT00125593) and the Improved 
Reduction of Outcomes: Vytorin Efficacy Inter-
national Trial (IMPROVE-IT) (NCT00202878).42 
Both trials tested the same study-drug combina-
tion that we used in our study, though in other 
patient populations and with a combined study 
population of nearly 20,000 patients. Cancer was 
one of a very large number of safety indicators 
analyzed in the SEAS trial, and the observed dif-
ference in cancer rates in the study may have 
been the result of chance, but this possibility re-
quires further study.
We conclude that in patients with mild-to-
moderate, asymptomatic aortic-valve stenosis and 
no traditional indications for lipid-lowering ther-
apy at baseline, long-term, intensive lipid-lowering 
therapy with simvastatin and ezetimibe had no 
overall effect on the course of aortic-valve stenosis. 
However, lipid-lowering therapy reduced the risk 
of ischemic cardiovascular events, especially the 
need for CABG. The higher incidence of cancer in 
the simvastatin–ezetimibe group requires further 
exploration in ongoing and future trials.
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Figure 4. Kaplan–Meier Curves for Cancer-Related Mortality.
P = 0.06 as calculated with log-rank continuity correction.
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